Caribou Biosciences, Inc. (CRBU) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Caribou Biosciences is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using its CRISPR chRDNA genome-editing platform. The company is currently advancing two primary clinical candidates: vispa-cel (anti-CD19) for B-cell non-Hodgkin lymphoma and CB-011 (anti-BCMA) for multiple myeloma. In April 2025, the company executed a strategic pipeline prioritization, discontinuing the GALLOP (lupus) and AMpLify (AML) trials and reducing its workforce by approximately 32%.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Licensing & Collaboration Revenue | $2,198 | $2,024 | $7,218 | $7,917 |
| Net Loss | $(27,548) | $(34,684) | $(121,637) | $(113,615) |
| Net Loss Per Share (Basic/Diluted) | $(0.30) | $(0.38) | $(1.31) | $(1.26) |
| Operating Expenses | $31,598 | $40,262 | $127,109 | $135,658 |
| Cash & Cash Equivalents | $11,144 | $16,293 | $11,144 | $16,293 |
| Total Cash, Equivalents & Marketable Securities | $159,212 | $249,386 | $159,212 | $249,386 |
| Accumulated Deficit | $(570,027) | $(412,900) | $(570,027) | $(412,900) |
Liquidity: Management expects existing cash, cash equivalents, and marketable securities of $159.2 million to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue: Q3 2025 revenue increased slightly by $0.2 million compared to Q3 2024. However, for the nine months ended September 30, 2025, revenue decreased by $0.7 million, primarily due to the absence of $1.6 million in revenue from Edge Animal Health (related party) recognized in the prior year.
- Expenses: Operating expenses decreased significantly in Q3 2025 ($8.7 million reduction) and for the nine-month period ($8.5 million reduction) compared to the prior year. This was driven by workforce reductions, lower external CRO/CMO costs, and reduced legal expenses.
- Impairment Charges: The company recorded $12.2 million in impairment charges for the nine months ended September 30, 2025, compared to zero in the prior year. This included $10.0 million for leasehold improvements, right-of-use assets, and lab equipment, and $2.2 million for unused lab equipment, resulting from the strategic pipeline prioritization.
- Equity Investment Impairment: A non-cash impairment charge of $9.2 million was recorded for the equity investment in Edge Animal Health, reducing the carrying value to zero.
- Other Income: Other income decreased due to lower interest income from marketable securities and the reversal of the MSKCC success payments liability (which was re-measured to zero following the termination of the MSKCC agreement).
Guidance, Outlook, and Risks
- Clinical Progress:
- vispa-cel: Data from the ANTLER Phase 1 trial showed an 82% overall response rate (ORR) and 64% complete response (CR) rate in a 22-patient confirmatory cohort. The company plans to evaluate vispa-cel in a pivotal Phase 3 trial in approximately 250 patients.
- CB-011: Dose escalation in the CaMMouflage Phase 1 trial is complete. The recommended dose for expansion is 450x10^6 viable CAR-T cells. Early data in a 12-patient BCMA-naïve cohort showed a 92% ORR and 75% CR rate.
- Capital Requirements: The company anticipates needing additional capital to fund the planned pivotal Phase 3 trial for vispa-cel and ongoing operations. It has a shelf registration statement allowing for up to $300 million in securities sales and an At-The-Market (ATM) program with $100 million available, though no shares were sold under the ATM program in the current period.
- Risks & Contingencies:
- Nasdaq Listing Compliance: The company received a notice in May 2025 regarding its stock price closing below $1.00 for 30 consecutive days. It regained compliance in June 2025 but faces ongoing risk of delisting if the price drops again. Shareholders have approved a reverse stock split (1-for-5 to 1-for-50) which the board may implement to maintain listing status.
- Litigation: A putative class action lawsuit (Saylor Case) and a consolidated shareholder derivative action were filed in 2024 and 2025, respectively. Both were voluntarily dismissed without prejudice in April and October 2025, respectively.
- Profitability: The company has incurred operating losses since inception and expects to continue incurring substantial losses. It has no products approved for commercial sale.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $159.2 million cash position to fund the planned Phase 3 trial for vispa-cel without immediate dilution.
- Stock Price & Listing Status: Monitor the stock price relative to the $1.00 Nasdaq minimum bid price requirement and the potential implementation of a reverse stock split.
- Phase 3 Trial Design: Confirm the final design and regulatory feedback for the pivotal vispa-cel Phase 3 trial, as this is critical for future valuation.
- Impairment Impact: Assess the long-term impact of the $12.2 million impairment charge on future depreciation and operating costs.
- Related Party Revenue: Note the reliance on related parties (Pfizer, Edge Animal Health) for a significant portion of revenue and the volatility associated with non-recurring related party transactions.